

Anna Maria Rachiglio

List of Publications by Citations

Source: <https://exaly.com/author-pdf/4380282/anna-maria-rachiglio-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

38
papers

1,477
citations

19
h-index

38
g-index

50
ext. papers

1,712
ext. citations

4.5
avg, IF

3.77
L-index

#	Paper	IF	Citations
38	The role of the EGFR signaling in tumor microenvironment. <i>Journal of Cellular Physiology</i> , 2008 , 214, 559-67	7	280
37	Leptin signaling in breast cancer: an overview. <i>Journal of Cellular Biochemistry</i> , 2008 , 105, 956-64	4.7	172
36	Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial. <i>Annals of Oncology</i> , 2015 , 26, 1710-4	10.3	101
35	Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next-generation sequencing: findings from the CAPRI-GOIM trial. <i>Annals of Oncology</i> , 2014 , 25, 1756-1761	10.3	91
34	Molecular typing of lung adenocarcinoma on cytological samples using a multigene next generation sequencing panel. <i>PLoS ONE</i> , 2013 , 8, e80478	3.7	88
33	Limits and potential of targeted sequencing analysis of liquid biopsy in patients with lung and colon carcinoma. <i>Oncotarget</i> , 2016 , 7, 66595-66605	3.3	67
32	Implementing anti-epidermal growth factor receptor (EGFR) therapy in metastatic colorectal cancer: challenges and future perspectives. <i>Annals of Oncology</i> , 2020 , 31, 30-40	10.3	58
31	RAS testing of liquid biopsy correlates with the outcome of metastatic colorectal cancer patients treated with first-line FOLFIRI plus cetuximab in the CAPRI-GOIM trial. <i>Annals of Oncology</i> , 2018 , 29, 112-118	10.3	57
30	Cetuximab continuation after first progression in metastatic colorectal cancer (CAPRI-GOIM): a randomized phase II trial of FOLFOX plus cetuximab versus FOLFOX. <i>Annals of Oncology</i> , 2016 , 27, 1055-1061	10.3	49
29	The S492R EGFR ectodomain mutation is never detected in KRAS wild-type colorectal carcinoma before exposure to EGFR monoclonal antibodies. <i>Cancer Biology and Therapy</i> , 2013 , 14, 1143-6	4.6	47
28	Molecular diagnostics and personalized medicine in oncology: challenges and opportunities. <i>Journal of Cellular Biochemistry</i> , 2013 , 114, 514-24	4.7	46
27	Development of a semi-conductor sequencing-based panel for genotyping of colon and lung cancer by the Onconetwork consortium. <i>BMC Cancer</i> , 2015 , 15, 26	4.8	42
26	Detection of KRAS mutations in colorectal carcinoma patients with an integrated PCR/sequencing and real-time PCR approach. <i>Pharmacogenomics</i> , 2010 , 11, 1169-79	2.6	39
25	Effects of the combined blockade of EGFR and ErbB-2 on signal transduction and regulation of cell cycle regulatory proteins in breast cancer cells. <i>Breast Cancer Research and Treatment</i> , 2010 , 123, 387-96	4.4	34
24	EPHA2 Is a Predictive Biomarker of Resistance and a Potential Therapeutic Target for Improving Antiepidermal Growth Factor Receptor Therapy in Colorectal Cancer. <i>Molecular Cancer Therapeutics</i> , 2019 , 18, 845-855	6.1	30
23	The Presence of Concomitant Mutations Affects the Activity of EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Patients. <i>Cancers</i> , 2019 , 11,	6.6	27
22	Detection of EGFR mutations by TaqMan mutation detection assays powered by competitive allele-specific TaqMan PCR technology. <i>BioMed Research International</i> , 2013 , 2013, 385087	3	27

21	Assessment of high-sensitive methods for the detection of EGFR mutations in circulating free tumor DNA from NSCLC patients. <i>Pharmacogenomics</i> , 2015 , 16, 1135-48	2.6	26
20	Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case. <i>ESMO Open</i> , 2018 , 3, e000299	6	24
19	Clinical outcome and molecular characterisation of chemorefractory metastatic colorectal cancer patients with long-term efficacy of regorafenib treatment. <i>ESMO Open</i> , 2017 , 2, e000177	6	19
18	Triple negative breast cancer: from molecular portrait to therapeutic intervention. <i>Critical Reviews in Eukaryotic Gene Expression</i> , 2010 , 20, 17-34	1.3	19
17	The role of circulating free DNA in the management of NSCLC. <i>Expert Review of Anticancer Therapy</i> , 2019 , 19, 19-28	3.5	17
16	BRAF V600E mutation in metastatic colorectal cancer: Methods of detection and correlation with clinical and pathologic features. <i>Cancer Biology and Therapy</i> , 2016 , 17, 840-8	4.6	16
15	Simultaneous detection of lung fusions using a multiplex RT-PCR next generation sequencing-based approach: a multi-institutional research study. <i>BMC Cancer</i> , 2018 , 18, 828	4.8	15
14	Genomic Profiling of Wild-Type Metastatic Colorectal Cancer Patients Reveals Novel Mutations in Genes Potentially Associated with Resistance to Anti-EGFR Agents. <i>Cancers</i> , 2019 , 11,	6.6	14
13	Activity of gefitinib in a non-small-cell lung cancer patient with both activating and resistance EGFR mutations. <i>Journal of Thoracic Oncology</i> , 2013 , 8, e59-60	8.9	14
12	Detection of KRAS mutations in colorectal cancer with Fast COLD-PCR. <i>International Journal of Oncology</i> , 2012 , 40, 378-84	4.4	12
11	AZD3409 inhibits the growth of breast cancer cells with intrinsic resistance to the EGFR tyrosine kinase inhibitor gefitinib. <i>Breast Cancer Research and Treatment</i> , 2007 , 102, 275-82	4.4	12
10	Cetuximab, irinotecan and fluorouracile in fiRst-line treatment of immunologically-selected advanced colorectal cancer patients: the CIFRA study protocol. <i>BMC Cancer</i> , 2019 , 19, 899	4.8	8
9	Clinical activity and tolerability of FOLFIRI and cetuximab in elderly patients with metastatic colorectal cancer in the CAPRI-GOIM first-line trial. <i>ESMO Open</i> , 2016 , 1, e000086	6	8
8	Study of Ras MutationsVPrognostic Value in Metastatic Colorectal Cancer: STORIA Analysis. <i>Cancers</i> , 2020 , 12,	6.6	6
7	Abstract 3575: The OncoNetwork Consortium: A global collaborative research study on the development and verification of an Ion AmpliSeq RNA gene lung fusion panel 2014 ,		4
6	Optimizing response to gefitinib in the treatment of non-small-cell lung cancer. <i>Pharmacogenomics and Personalized Medicine</i> , 2011 , 4, 1-9	2.1	2
5	Colorectal cancer genomic biomarkers in the clinical management of patients with metastatic colorectal carcinoma 2020 , 1, 53-70		2
4	Comment on V comparison of three methods for detecting KRAS mutations in formalin-fixed colorectal cancer specimensV <i>British Journal of Cancer</i> , 2012 , 107, 1791-2; author reply 1793-4	8.7	1

- 3 Letter to the Editor: Reply to Kobunai et al.. *Pharmacogenomics*, **2011**, 12, 309-310 2.6 1
- 2 Liquid Biopsy Testing for the Management of Patient with Non-Small Cell Lung Cancer Carrying a Rare Exon-20 EGFR Insertion.. *Oncologist*, **2022**, 27, 7-12 5.7 0
- 1 Circulating Tumor Cells and ctDNA in NSCLC **2019**, 465-475